<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="if they are 4 months or longer posttransplant. Chemoprophylaxis with" exact="oseltamivir" post="or zanamivir should also be initiated for 2 weeks"/>
 <result pre="are 4 months or longer posttransplant. Chemoprophylaxis with oseltamivir or" exact="zanamivir" post="should also be initiated for 2 weeks after vaccination"/>
 <result pre="24 months who are profoundly immunocompromised may be considered for" exact="palivizumab" post="prophylaxis. The development of a potent and long-acting RSV"/>
 <result pre="studies, including a pooled analysis, have shown aerosolized or oral" exact="ribavirin" post="is protective against disease progression to lower respiratory tract"/>
 <result pre="In patients with leukemia, multivariate models demonstrated similar effects.33 Oral" exact="ribavirin" post="has been retrospectively evaluated in patients receiving chemotherapy or"/>
 <result pre="patients with RSV lower respiratory tract infection, use of aerosolized" exact="ribavirin" post="was associated with decreased mortality. Oral or IV ribavirin"/>
 <result pre="aerosolized ribavirin was associated with decreased mortality. Oral or IV" exact="ribavirin" post="although not statistically significant as the effect was smaller.11,12"/>
 <result pre="recipients with RSV have little morbidity and mortality even without" exact="ribavirin" post="therapy.35 Current international guidelines recommend aerosolized or systemic (oral"/>
 <result pre="Current international guidelines recommend aerosolized or systemic (oral or IV)" exact="ribavirin" post="with intravenous immunoglogulin (IVIG) in patients with RSV upper"/>
 <result pre="allogeneic HCT patients with lower respiratory tract infection.36 Recommendations for" exact="ribavirin" post="administration for HCT and SOT recipients, and oncology patients"/>
 <result pre="Table 21.1 . Most data and guidance for use of" exact="ribavirin" post="are in HCT and oncology; few studies have clearly"/>
 <result pre="data are in lung transplant when both oral and IV" exact="ribavirin" post="have been used,37 For HCT and oncology patients, high-risk"/>
 <result pre="could be used to further risk-stratify patients. In general, aerosolized" exact="ribavirin" post="is reserved for subjects with virologically confirmed (BAL positive"/>
 <result pre="3 times daily. Aerosol administration results in high levels of" exact="ribavirin" post="in the secretions, with levels exceeding 1000 μM and"/>
 <result pre="μM and little systemic absorption. The potential environmental release of" exact="ribavirin" post="has caused concern in hospital personnel because of the"/>
 <result pre="concern in hospital personnel because of the potential teratogenicity of" exact="ribavirin" post="and thus exposure is contraindicated in pregnant women because"/>
 <result pre="in pregnant women because of its teratogenic potential. Administration of" exact="ribavirin" post="via a ventilator, using a high-dose, short-duration method of"/>
 <result pre="a vacuum-exhausted treatment hood, results in minimal or no detectable" exact="ribavirin" post="in the rooms of treated children. TABLE 21.1 Prevention"/>
 <result pre="Oncology: Ribavirin for high-risk situationsa,b,c •SOT: limited data; consider oral" exact="ribavirin" post="in lung transplant •Isolation •Low-risk situations in HCT and"/>
 <result pre="oral ribavirinb •High-risk situations in HCT and oncology: consider aerosolized" exact="ribavirin" post="initially followed by oralb,c •SOT: consider oral or aerosolized"/>
 <result pre="ribavirin initially followed by oralb,c •SOT: consider oral or aerosolized" exact="ribavirin" post="in lung transplant •Supportive care Influenza A/B •Infection control"/>
 <result pre="anti−B-cell antibodies in the past 6 months •Isolation •Oseltamivir or" exact="zanamivir" post="•Isolation •Oseltamivir or zanamivir •Isolation •Oseltamivir or zanamivir •Consider"/>
 <result pre="past 6 months •Isolation •Oseltamivir or zanamivir •Isolation •Oseltamivir or" exact="zanamivir" post="•Isolation •Oseltamivir or zanamivir •Consider combination therapy with baloxavir"/>
 <result pre="•Oseltamivir or zanamivir •Isolation •Oseltamivir or zanamivir •Isolation •Oseltamivir or" exact="zanamivir" post="•Consider combination therapy with baloxavir if ≥ 12 years,"/>
 <result pre="•Consider combination therapy with baloxavir if ≥ 12 years, or" exact="rimantadine" post="(only influenza A) and/or ribavirin •Consider IV peramivir if"/>
 <result pre="if ≥ 12 years, or rimantadine (only influenza A) and/or" exact="ribavirin" post="•Consider IV peramivir if mechanically ventilated •Supportive care PIV"/>
 <result pre="years, or rimantadine (only influenza A) and/or ribavirin •Consider IV" exact="peramivir" post="if mechanically ventilated •Supportive care PIV •Infection control procedures"/>
 <result pre="•Isolation •Consider reduction of steroid dose •Isolation •Supportive care •Consider" exact="ribavirin" post="if mechanically ventilatedb HMPV •Infection control procedures •Isolation •Isolation"/>
 <result pre="HMPV •Infection control procedures •Isolation •Isolation •Isolation •Supportive care •Consider" exact="ribavirin" post="if mechanically ventilatedb HRV •Infection control procedures •Isolation •Isolation"/>
 <result pre="the use of aerosolized ribavirin. bBenefit and dosing of oral" exact="ribavirin" post="not clearly understood. cHigh risk: lymphopenia, smoking history, and"/>
 <result pre="lymphopenia, smoking history, and use of high-dose total-body irradiation. Oral" exact="ribavirin" post="can be considered in patients weighing more than 15kg;"/>
 <result pre="treat RSV disease. The combination of high-titer RSV immunoglobulin and" exact="ribavirin" post="has been associated with therapeutic success in uncontrolled studies"/>
 <result pre="lower respiratory tract infection suggested a beneficial effect of adjunctive" exact="palivizumab" post="or IVIG.38 Larger studies of HCT recipients with RSV"/>
 <result pre="infection were unable to demonstrate improved outcomes with adjunctive palivizumab11,12;" exact="palivizumab" post="is not currently recommended for treatment of RSV infection"/>
 <result pre="of RSV infection in any immunocompromised patients. The duration of" exact="ribavirin" post="therapy in immunocompromised hosts is generally at least 3"/>
 <result pre="oseltamivir, inhaled zanamivir, IV peramivir, and baloxavir. Clinical efficacy with" exact="oseltamivir" post="and inhaled zanamivir has been demonstrated in patients with"/>
 <result pre="IV peramivir, and baloxavir. Clinical efficacy with oseltamivir and inhaled" exact="zanamivir" post="has been demonstrated in patients with leukemia or HCT"/>
 <result pre="in patients with leukemia or HCT recipients.18 Many mutations causing" exact="oseltamivir" post="and peramivir resistance, including the common H275Y mutation in"/>
 <result pre="with leukemia or HCT recipients.18 Many mutations causing oseltamivir and" exact="peramivir" post="resistance, including the common H275Y mutation in A(H1N1)pdm09 influenza,"/>
 <result pre="A(H1N1)pdm09 influenza, do not confer resistance to zanamivir40 and inhaled" exact="zanamivir" post="may be used to treat these strains. IV peramivir"/>
 <result pre="inhaled zanamivir may be used to treat these strains. IV" exact="peramivir" post="used during the 2009 pandemic in severely ill patients"/>
 <result pre="recovery in most patients.41 In a randomized trial comparing IV" exact="peramivir" post="to oral oseltamivir in hospitalized adults, clinical outcomes were"/>
 <result pre="patients.41 In a randomized trial comparing IV peramivir to oral" exact="oseltamivir" post="in hospitalized adults, clinical outcomes were similar.42 The optimal"/>
 <result pre="hospitalized adults, clinical outcomes were similar.42 The optimal duration of" exact="peramivir" post="therapy has not been determined for immunocompromised hosts. Longer"/>
 <result pre="Longer treatment courses (10 days), although not higher doses, with" exact="oseltamivir" post="or zanamivir have been suggested, given the potential for"/>
 <result pre="courses (10 days), although not higher doses, with oseltamivir or" exact="zanamivir" post="have been suggested, given the potential for recurrence and"/>
 <result pre="in immunocompromised patients. Triple-combination antiviral therapy with amantadine, ribavirin, and" exact="oseltamivir" post="has been proposed to treat immunocompromised patients with severe"/>
 <result pre="to oseltamivir. A randomized trial comparing triple-combination antiviral therapy with" exact="oseltamivir" post="alone in high-risk adults demonstrated an effect on viral"/>
 <result pre="of patients with leukemia or HCT recipients with PIV infection," exact="ribavirin" post="had no impact on viral shedding, symptom and hospitalization"/>
 <result pre="infection, or mortality.45 A systematic review evaluated aerosolized or systemic" exact="ribavirin" post="in 10 retrospective studies in this same population and"/>
 <result pre="respiratory tract infection.46 Given lack of evidence of clinical efficacy," exact="ribavirin" post="is not recommended for PIV infections. The impact of"/>
 <result pre="hosts (with and without IVIG). Lack of controlled studies of" exact="ribavirin" post="and the known toxicities of therapy, including hemolytic anemia,"/>
 <result pre="novel influenza therapeutics are under investigation, including the NAIs IV" exact="zanamivir" post="and laninamivir, monoclonal antibodies, viral polymerase inhibitors, and nitazoxanide."/>
 <result pre="organ transplantationAm J Transplant13suppl 4201321221923465014 29.IsonMGSzakalyPShapiraMYKrivanGNistADutkowskiREfficacy and safety of oral" exact="oseltamivir" post="for influenza prophylaxis in transplant recipientsAntivir Ther176201295596422728756 30.RalstonSLLieberthalASMeissnerHCClinical practice"/>
 <result pre="management, and prevention of bronchiolitisPediatrics13452014e147450225349312 31.Reassessment of the indications for" exact="ribavirin" post="therapy in respiratory syncytial virus infectionsAmerican Academy of Pediatrics"/>
 <result pre="syncytial virus infection in patients with leukemiaHaematologica92920071216162317666367 34.FooladFAitkenSLShigleTLOral versus aerosolized" exact="ribavirin" post="for the treatment of respiratory syncytial virus infections in"/>
 <result pre="cell transplantation recipientsClin Infect Dis2018doi: 10.1093/cid/ciy760 35.El-Bietar JNelsonAWallaceGRSV infection without" exact="ribavirin" post="treatment in pediatric hematopoietic stem cell transplantationBone Marrow Transplant511020161382138427183091"/>
 <result pre="virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirusClin Infect Dis562201325826623024295 37.BurrowsFSCarlosLMBenzimraMOral" exact="ribavirin" post="for respiratory syncytial virus infection after lung transplantation: efficacy"/>
 <result pre="320131823 41.HernandezJEAdigaRArmstrongRClinical experience in adults and children treated with intravenous" exact="peramivir" post="for 2009 influenza A (H1N1) under an emergency IND"/>
 <result pre="the United StatesClin Infect Dis526201169570621367722 42.IsonMGHuiDSClezyKA clinical trial of intravenous" exact="peramivir" post="compared with oral oseltamivir for the treatment of seasonal"/>
 <result pre="Dis526201169570621367722 42.IsonMGHuiDSClezyKA clinical trial of intravenous peramivir compared with oral" exact="oseltamivir" post="for the treatment of seasonal influenza in hospitalized adultsAntivir"/>
 <result pre="in adults and adolescentsN Engl J Med37910201891392330184455 44.BeigelJHBaoYBeelerJOseltamivir, amantadine, and" exact="ribavirin" post="combination antiviral therapy versus oseltamivir monotherapy for the treatment"/>
 <result pre="J Med37910201891392330184455 44.BeigelJHBaoYBeelerJOseltamivir, amantadine, and ribavirin combination antiviral therapy versus" exact="oseltamivir" post="monotherapy for the treatment of influenza: a multicentre, double-blind,"/>
</results>
